BLU-808 for Allergic Rhinoconjunctivitis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test a new treatment called BLU-808 for individuals with allergic rhinoconjunctivitis caused by ragweed pollen. The study will assess the drug's safety, tolerability, behavior in the body, and effectiveness in reducing allergy symptoms. Participants will receive either one of two doses of BLU-808 or a placebo (a pill with no active drug) for 28 days. Suitable candidates have had ragweed allergies for more than two years, experience nasal and eye symptoms when exposed to ragweed, and have a positive recent skin test for ragweed. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to potential advancements in allergy treatment.
Do I need to stop taking my current medications for the trial?
Yes, you will need to stop taking any medications for ragweed or other allergy symptoms, as well as any medications that could affect your safety or interfere with the study results.
Is there any evidence suggesting that BLU-808 is likely to be safe for humans?
Research shows that BLU-808 is generally well-tolerated by most participants. Studies have found it to be safe at various dose levels, with serious side effects being uncommon. Some participants might experience mild side effects, but these are usually manageable. Although exact numbers are not available, this trial aims to confirm the safety of BLU-808, indicating its promise in earlier research.12345
Why do researchers think this study treatment might be promising for allergic rhinoconjunctivitis?
Unlike the standard treatments for allergic rhinoconjunctivitis, like antihistamines and corticosteroids, BLU-808 offers a fresh approach by being an orally administered option with potentially faster and more sustained relief. Researchers are particularly excited about BLU-808 because it targets specific pathways involved in the allergic response, potentially offering more precise control over symptoms. This targeted mechanism could mean fewer side effects compared to traditional options, making it a promising candidate for those who haven't found relief with existing medications.
What evidence suggests that BLU-808 might be an effective treatment for allergic rhinoconjunctivitis?
Research has shown that BLU-808 may help treat allergic rhinoconjunctivitis (ARC), which includes symptoms like sneezing, itching, and a runny nose. In earlier studies, participants taking BLU-808 experienced a 54.2% improvement in symptoms, compared to 40.8% for those taking a placebo. This trial will test different doses of BLU-808, with some participants receiving BLU-808 Dose 1, others receiving BLU-808 Dose 2, and a separate group receiving a placebo. These findings suggest that BLU-808 could effectively reduce allergy symptoms. The treatment is an easy-to-take pill. While more research is needed, early results are promising for those with ragweed-induced ARC.46789
Are You a Good Fit for This Trial?
Adults over 18 with a history of ragweed-induced allergic rhinoconjunctivitis (ARC) for more than two years, who have had a positive skin test for ragweed. Participants must show significant nasal and eye symptoms from ARC to join the study.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BLU-808 or placebo orally for 28 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BLU-808
Trial Overview
The trial is testing BLU-808's effects on people with ARC caused by ragweed pollen. It will look at how safe it is, how the body processes it, and its early effectiveness compared to a placebo (a substance with no active drug).
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
BLU-808 will be administered orally for 28 days.
BLU-808 will be administered orally for 28 days.
Placebo will be administered orally for 28 days.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Blueprint Medicines Corporation
Lead Sponsor
Published Research Related to This Trial
Citations
BLU-808 for Allergic Rhinoconjunctivitis
What data supports the effectiveness of the drug BLU-808 for treating allergic rhinoconjunctivitis? ... outcomes compared to 40.8% in the placebo group.
2.
centerwatch.com
centerwatch.com/clinical-trials/listings/NCT06922448/study-of-blu-808-in-allergic-rhinoconjunctivitisStudy of BLU-808 in Allergic Rhinoconjunctivitis
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of ...
Allergic Rhino-Conjunctivitis Market Poised for Significant ...
Blueprint Medicines is also evaluating BLU-808 for allergic rhino-conjunctivitis in Canada; however, the company's current focus on securing ...
4.
blueprintmedicines.com
blueprintmedicines.com/wp-content/uploads/2025/02/Blueprint-Medicines-AAAAI-WAO-2025-BLU-808-Wild-Type-KIT-Inhibitor-Poster.pdfBLU-808: A Potent and Selective Oral Small Molecule Wild ...
spontaneous and inducible urticarias, allergic rhinoconjunctivitis, allergic asthma, and mast cell ... BLU-808 was able to improve lung ...
5.
expertmarketresearch.com
expertmarketresearch.com/clinical-trials/allergic-conjunctivitis-pipeline-insightAllergic Conjunctivitis Pipeline Insight 2025
The study is examining BLU-808's effectiveness in reducing symptoms following controlled ragweed pollen exposure in an allergen exposure chamber. *Please ...
Study of BLU-808 in Allergic Rhinoconjunctivitis
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants ...
BLU-808
Long-term safety was also assessed. RESULTS: A total of 226 patients initiated 25 mg once-daily (QD) avapritinib including 75 patients who received placebo ...
8.
prnewswire.com
prnewswire.com/news-releases/blueprint-medicines-provides-2025-outlook-and-highlights-strategy-for-continued-growth-302348688.htmlBlueprint Medicines Provides 2025 Outlook and Highlights ...
Detailed data will be presented at the J.P. Morgan conference. Safety: BLU-808 was well-tolerated at all doses tested. All treatment ...
9.
rarediseaseadvisor.com
rarediseaseadvisor.com/news/blueprint-medicines-projects-continued-growth-sm-inflammatory-disease-programs/Blueprint Medicines Forecasts Continued Growth in 2025
BLU 808 demonstrated a favorable safety profile, mast cell target engagement across multiple dose levels, and reductions in tryptase levels ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.